{"ModuleTitle": "Company Description", "CompanyName": "Merrimack Pharmaceuticals, Inc.", "Symbol": "MACK", "Address": "ONE BROADWAY 14TH FLOOR, CAMBRIDGE, Massachusetts, 02142, United States of America", "Phone": "617-441-1000", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biopharmaceutical company based in Cambridge, Massachusetts that is\r\nentitled to receive up to $450.0 million in contingent milestone payments\r\nrelated to our sale of ONIVYDE\u00ae to Ipsen S.A., or Ipsen, in April 2017 and up to\r\n$54.5 million in contingent milestone payments related to our sale of MM-121 and\r\nMM-111 to Elevation Oncology, Inc. (formerly known as 14ner Oncology, Inc.), or\r\nElevation, in July 2019. We do not have any ongoing research or development\r\nactivities and are seeking potential acquirers for our remaining preclinical and\r\nclinical assets. We do not have any employees and instead use external\r\nconsultants for the operation of our company.\r\n\r\nOn April 3, 2017, we completed the sale of ONIVYDE and MM-436 (the \"commercial\r\nbusiness\") to Ipsen (the \"Ipsen sale\"). At the time of the sale ONIVYDE was\r\napproved in the United States for the second line treatment of metastatic\r\nadenocarcinoma of the pancreas.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f12%2f0001564590-20-010531.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Gary L. Crocker", "title": "Chairman, President, CEO, CFO & Treasurer"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}